Abiopharma

Riverstone Holdings Limited - Announcement

New Form EFFECT - SenesTech, Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002731 Size: 1 KB

New Form 8-K - scPharmaceuticals Inc. Filed: 2025-08-25 AccNo: 0001193125-25-186947 Size: 166 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form 8-K - Theravance Biopharma, Inc. Filed: 2025-08-25 AccNo: 0001104659-25-082048 Size: 231 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form EFFECT - Armata Pharmaceuticals, Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002726 Size: 1 KB

New Form EFFECT - ProMIS Neurosciences Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002725 Size: 1 KB

New Form EFFECT - Absci Corp Filed: 2025-08-22 AccNo: 9999999995-25-002723 Size: 1 KB

New Form EFFECT - Candel Therapeutics, Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002727 Size: 1 KB

New Form EFFECT - DiaMedica Therapeutics Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002724 Size: 1 KB

New Form EFFECT - Phio Pharmaceuticals Corp. Filed: 2025-08-22 AccNo: 9999999995-25-002730 Size: 1 KB

New Form EFFECT - Erasca, Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002722 Size: 1 KB

New Form EFFECT - Protalix BioTherapeutics, Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002712 Size: 1 KB

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

General Announcement: Monthly update pursuant to Catalist Rule 704(22)